OUTCOME ASSESSMENTS OF PRIMARY ENDPOINTS OF NEW DRUGS APPROVED BY THE FDA (2011-2015) [MEETING ABSTRACT PHP101]
studies of recent FDA approvals. PROs were key to assess treatment benefit in diseases such as those related to genitourinary, digestive and musculoskeletal systems as per respective regulatory guidance.
Citation
Gnanasakthy, A., & DeMuro, C. (2016). OUTCOME ASSESSMENTS OF PRIMARY ENDPOINTS OF NEW DRUGS APPROVED BY THE FDA (2011-2015) [MEETING ABSTRACT PHP101]. Value in Health, 19(3), A275-A275. https://doi.org/10.1016/j.jval.2016.03.1962
